ERBB2 and neoplasm: In two xenograft mouse models, CAR macrophages (CAR-M) targeting solid tumor antigens mesothelin or HER2 reduced tumor burden and prolonged overall survival, preliminarily proving its feasibility in solid tumors (69, 70).